Fennec Pharmaceuticals, Inc.

Pending

Securities Fraud Class Action Against Fennec Pharmaceuticals, Inc.

Roche Freedman is actively litigating this federal securities class action, Chapman v. Fennec Pharmaceuticals, Inc. et al., No 1:20-cv-00812-UA-JLW, seeking to help shareholders recover losses due to alleged securities fraud between December 20, 2018 and August 10, 2020, inclusive.

The current complaint, filed on February 1, 2021, alleges that Fennec Pharmaceuticals, Inc. ("Fennec") and certain corporate insiders made materially false and/or misleading statements concerning the Companies ability to achieve FDA approval of its New Drug Application ("NDA") for PEDMARK.  While Fennec stock was trading at an all-time high in anticipation of FDA approval, the Company announced that it had received a Complete Response Letter, rejecting the NDA for PEDMAREK.  As a result of Defendants' wrongful acts and omissions, Fennec stock traded at artificially inflated prices, and when the truth came out, the stock price crashed - causing shareholders to lose money.

On March 30, 2022, Lead Plaintiff, Daniel Malakoi, filed a motion for post-judgment relief to amend the complaint following the Court's March 2, 2022 order dismissing the case with prejudice.  The proposed amended complaint seeks to recover losses on behalf of Fennec shareholders who were adversely affected by alleged securities fraud between December 20, 2018 and November 28, 2021.  

For More Information:

If you purchased Fennec stock between December 20,2018 and November 28, 2021, and would like us to evaluate your claim and/or for more information about the lawsuit, please submit your information.